Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarantus Bioscience Holdings (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit.
Subscribe to our email newsletter
Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.
"We are extremely pleased to enter into this agreement that further positions Amarantus within the cell cycle dysregulation field in Alzheimer’s disease," said Gerald E. Commissiong, President & CEO of Amarantus.
"We believe new concepts and ideas are required to make progress in treating this devastating disorder, and we believe Dr. Arendt’s pioneering work that led to LymPro also has therapeutic applications. We look forward to working with the University to execute definitive agreements."
Dr. Arendt has filed international patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer’s disease using gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to be at the root of Alzheimer’s pathology.
The Company is currently developing an Alzheimer’s blood diagnostic LymPro Test(R) capable of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility of a targeted therapeutic on those Alzheimer’s patients that have tested positive for LymPro.